Analyses of Kite's Yescarta® CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin Lymphomas -December 11, 2023 at 09:01 pm EST

– ZUMA-1 Post-Hoc Analysis Shows Five-Year Lymphoma-Related Event-Free Survival in a Substantial Proportion of Patients with Refractory Large B-cell Lymphoma –


– Four-Year Follow-up from...

Related Keywords

United States ,California ,Santa Monica ,Texas ,Amsterdam ,Noord Holland ,Netherlands ,Foster City ,American ,Axicabtagene Ciloleucel ,Frank Neumann ,Marie Jos ,Gilead Sciences ,Gilead Company ,Exchange Commission ,Amsterdam University Medical Centers ,American Society Of Hematology ,Gilead Company Nasdaq ,University Of Texas Md Anderson Cancer Center ,Global Head Of Clinical Development ,Gilead Sciences Inc ,American Society ,Annual Meeting ,Senior Vice President ,Global Head ,Clinical Development ,Yescarta Abstracts ,Exploratory Long Term Survival Assessment ,Refractory Largeb Cell Lymphoma ,Confidence Interval ,Refractory Indolent Non Hodgkin Lymphoma ,Year Follow Up ,Overall Survival With Axicabtagene Ciloleucel ,Second Line Largeb Cell Lymphoma Among ,Subgroup Analysis ,Professor Marie Jos ,Amsterdam University Medical ,Risk Evaluation ,Mitigation Strategy ,Important Safety ,Release Syndrome ,Private Securities Litigation Reform Act ,Quarterly Report ,Markets ,